{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:39:43Z","timestamp":1774330783540,"version":"3.50.1"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Fibrolamellar carcinoma (FLC) is a rare but fatal cancer that occurs primarily in young people. There are currently no known effective treatments, although several promising treatments appear to be in development. Genetic studies have confirmed that almost all FLC tumors have a fusion protein marker (DNAJB1-PRKACA) encoded by a fusion gene (DNAJB1-PRKACA); It is currently accepted as a diagnostic criterion for FLCs. Several research teams have established patient-derived xenograft (PDX) FLC models using immunocompromised animals as hosts and patient tissue samples (tumors or ascites) as primary sources for PDX-derived organoids. These FLC organoids are composed of FLC epithelia, endothelial progenitor cells, and stellate cells. CRISPR\/Cas9 was used as a gene editing technique to modify mature hepatocytes to obtain <jats:italic>ex vivo<\/jats:italic> FLC-like cells expressing the fusion gene and\/or other mutated genes associated with FLCs. Although these models simulate some but not all FLC features. Drug screening using these models has not proven effective in identifying clinically useful treatments. Genetic studies comparing FLCs to normal maturing endodermal cell lineages have shown that FLCs share genetic signatures not with hepatocytes, but with subpopulations of biliary tree stem cells (BTSCs), hepato\/pancreatic stem\/progenitor cells that consistently reside in peribiliary glands (PBGs) located in the biliary tree and are sources of stem cells for the formation and postnatal regeneration of the liver and pancreas. Therefore, it is expected that models of BTSCs, instead of hepatocytes may prove more useful. In this review, we summarize the status of the various FLC models and their features, applications, and limitations. They provide opportunities to understand the cause and characteristics of this deadly disease and are models from which effective treatments can be identified.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1459942","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:10:11Z","timestamp":1731046211000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Models of fibrolamellar carcinomas, tools for evaluation of a new era of treatments"],"prefix":"10.3389","volume":"15","author":[{"given":"Jinjia","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengqi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiying","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wencheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00580-3","article-title":"A framework for fibrolamellar carcinoma research and clinical trials","volume":"19","author":"Dinh","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6064\/2012\/743790","article-title":"Fibrolamellar carcinoma: 2012 update","volume":"743790","author":"Torbenson","year":"2012","journal-title":"Scientifica"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800715)46:2<372::AID-CNCR2820460227>3.0.CO;2-S","article-title":"Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features","volume":"46","author":"Craig","year":"1980","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"8070","DOI":"10.1038\/ncomms9070","article-title":"Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells","volume":"6","author":"Oikawa","year":"2015","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1956.02060020170015","article-title":"Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood","volume":"91","author":"Edmondson","year":"1956","journal-title":"A.M.A. J Dis Children"},{"key":"B6","first-page":"3","article-title":"Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium","volume":"6","author":"Ang","year":"2013","journal-title":"Gastrointestinal Cancer Research: GCR"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/2050640613501507","article-title":"Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database","volume":"1","author":"Eggert","year":"2013","journal-title":"United Eur Gastroenterol J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.864106","article-title":"Epidemiological and clinical characteristics of five rare pathological subtypes of hepatocellular carcinoma","volume":"12","author":"Chen","year":"2022","journal-title":"Front In Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S215235","article-title":"Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma","volume":"6","author":"Zakka","year":"2019","journal-title":"J Hepatocellular Carcinoma"},{"key":"B10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12957-020-01855-2","article-title":"Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience","volume":"18","author":"Lemekhova","year":"2020","journal-title":"World J Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-023-05621-z","article-title":"Treatment and prognosis of fibrolamellar hepatocellular carcinoma: a systematic review of the recent literature and meta-analysis","volume":"27","author":"Glavas","year":"2023","journal-title":"J Gastrointestinal Surgery: Off J Soc For Surg Alimentary Tract"},{"key":"B12","first-page":"3","article-title":"Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma:data from the fibrolamellar carcinoma consortium","volume":"6","author":"Ang","year":"2013","journal-title":"Gastrointestinal Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.1249484","article-title":"Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinomas","volume":"343","author":"Honeyman","year":"2014","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28307","article-title":"The DNAJB1-PRKACA chimera: Candidate biomarker and therapeutic target for fibrolamellar carcinomas","volume":"63","author":"Reid","year":"2015","journal-title":"Hepatol (Hepatology Elsewhere)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e44187","DOI":"10.7554\/eLife.44187.023","article-title":"An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma","volume":"8","author":"Turnham","year":"2019","journal-title":"Elife"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.4","article-title":"DNAJB1-PRKACA is specific for fibrolamellar carcinoma","volume":"28","author":"Graham","year":"2015","journal-title":"Modern Pathology: an Off J United States Can Acad Pathology Inc"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.09.008","article-title":"CRISPR\/cas9 engineering of adult mouse liver demonstrates that the dnajb1-prkaca gene fusion is sufficient to induce tumors resembling fibrolamellar hepatocellular carcinoma","volume":"153","author":"Engelholm","year":"2017","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1716483114","article-title":"DNAJB1-PRKACA fusion kinase interacts with \u03b2-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma","volume":"114","author":"Kastenhuber","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29719","article-title":"Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion","volume":"68","author":"Graham","year":"2018","journal-title":"Hepatol (Baltimore Md.)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.12.006","article-title":"BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA","volume":"72","author":"Hirsch","year":"2020","journal-title":"J Hepatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41467-018-04252-2","article-title":"The CRISPR tool kit for genome editing and beyond","volume":"9","author":"Adli","year":"2018","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature13589","article-title":"CRISPR-mediated direct mutation of cancer genes in the mouse liver","volume":"514","author":"Xue","year":"2014","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1512392112","article-title":"CRISPR\/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice","volume":"112","author":"Weber","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B26","doi-asserted-by":"publisher","first-page":"10770","DOI":"10.1038\/ncomms10770","article-title":"Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR\/Cas9 delivery in mice","volume":"7","author":"Maresch","year":"2016","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7391","DOI":"10.1038\/ncomms8391","article-title":"Somatic CRISPR\/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling","volume":"6","author":"Zuckermann","year":"2015","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.09.014","article-title":"CRISPR-Cas9 knockin mice for genome editing and cancer modeling","volume":"159","author":"Platt","year":"2014","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1038\/s41467-023-37951-6","article-title":"Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss","volume":"14","author":"R\u00fcland","year":"2023","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2019.01.008","article-title":"MicroRNA-375 suppresses the growth and invasion of fibrolamellar carcinoma","volume":"7","author":"Dinh","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"44653","DOI":"10.1038\/srep44653","article-title":"Comprehensive analysis of the cancer genome atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma","volume":"7","author":"Dinh","year":"2017","journal-title":"(Nature) Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"107509","DOI":"10.1016\/j.celrep.2020.03.073","article-title":"Hotspots of aberrant enhancer activity in fibrolamellar carcinoma reveal candidate oncogenic pathways and therapeutic vulnerabilities","volume":"31","author":"Dinh","year":"2020","journal-title":"Cell Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"C151","DOI":"10.1152\/ajpcell.00120.2020","article-title":"A brief history of organoids","volume":"319","author":"Corr\u00f2","year":"2020","journal-title":"Am J Physiol Cell Physiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s004410050974","article-title":"Tissue engineering: generation of differentiated artificial tissues for biomedical applications","volume":"291","author":"Minuth","year":"1998","journal-title":"Cell Tissue Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.082","article-title":"Modeling development and disease with organoids","volume":"165","author":"Clevers","year":"2016","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4438","article-title":"Human primary liver cancer-derived organoid cultures for disease modeling and drug screening","volume":"23","author":"Broutier","year":"2017","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e2003897","DOI":"10.1002\/advs.202003897","article-title":"Single-cell transcriptome analysis uncovers intratumoral heterogeneity and underlying mechanisms for drug resistance in hepatobiliary tumor organoids","volume":"8","author":"Zhao","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12943-021-01426-3","article-title":"Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine","volume":"20","author":"Pamarthy","year":"2021","journal-title":"Mol Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1038\/s41467-021-22676-1","article-title":"Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week","volume":"12","author":"Hu","year":"2021","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0474","article-title":"Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids","volume":"8","author":"Hill","year":"2018","journal-title":"Cancer Discovery"},{"key":"B41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A living biobank of breast cancer organoids captures disease heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2022.06.003","article-title":"Human liver organoids for disease modeling of fibrolamellar carcinoma","volume":"17","author":"Narayan","year":"2022","journal-title":"Stem Cell Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-020-01990-z","article-title":"Cancer research using organoid technology","volume":"99","author":"Kretzschmar","year":"2021","journal-title":"J Mol Med (Berl)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.22.12132","article-title":"Clonogenic hepatoblasts, common precursors for hepatocytic and biliary lineages, are lacking classical major histocompatibility complex class I antigen","volume":"97","author":"Kubota","year":"2000","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-023-1002-1","article-title":"Liver cell therapies: cellular sources and grafting strategies","volume":"17","author":"Zhang","year":"2023","journal-title":"Front Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.69521.sa2","article-title":"Oncogenic PKA signaling increases c-MYC protein expression through multiple targetable mechanisms","volume":"12","author":"Chan","year":"2023","journal-title":"Elife"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0872","article-title":"Identification of novel therapeutic targets for fibrolamellar carcinoma using patient-derived xenografts and direct-from-patient screening","volume":"11","author":"Lalazar","year":"2021","journal-title":"Cancer Discovery"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.17-0062","article-title":"An animal model of local breast cancer recurrence in the setting of autologous fat grafting for breast reconstruction","volume":"7","author":"Tsuji","year":"2018","journal-title":"Stem Cells Transl Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15532","article-title":"High incidence of lymph-node metastasis in a pancreatic-cancer patient-derived orthotopic xenograft (PDOX) NOG-mouse model","volume":"42","author":"Sugisawa","year":"2022","journal-title":"Anticancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.005","article-title":"A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer","volume":"65","author":"Asgharpour","year":"2016","journal-title":"J Hepatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"pdb.top069948","DOI":"10.1101\/pdb.top069948","article-title":"Methods to study metastasis in genetically modified mice","volume":"2016","author":"Kabeer","year":"","journal-title":"Cold Spring Harb Protoc"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1618389114","article-title":"Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts","volume":"114","author":"Fior","year":"2017","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.11.034","article-title":"Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish","volume":"70","author":"de Oliveira","year":"2019","journal-title":"J Hepatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.06.164","article-title":"Inducible liver-specific overexpression of gankyrin in zebrafish results in spontaneous intrahepatic cholangiocarcinoma and hepatocellular carcinoma formation","volume":"490","author":"Huang","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.042564","article-title":"DnaJ-PKAc fusion induces liver inflammation in a zebrafish model of fibrolamellar carcinoma","volume":"13","author":"de Oliveira","year":"2020","journal-title":"Dis Models Mech"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606857","article-title":"Genetically engineered mouse models in oncology research and cancer medicine","volume":"9","author":"Kersten","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23325","article-title":"Non coding RNA analysis in fibrolamellar hepatocellular carcinoma","volume":"9","author":"Farber","year":"2018","journal-title":"Oncotarget"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1235","article-title":"Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice","volume":"3","author":"Rangarajan","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000499581","article-title":"Hepatocellular carcinoma of fibrolamellar type in an adolescent: case report and literature review","volume":"6","author":"Santiago-Reynoso","year":"2019","journal-title":"Gastrointestinal Tumors"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-21-0177","article-title":"Chemical, molecular, and single cell analysis reveal chondroitin sulfate proteoglycan aberrancy in fibrolamellar carcinomas","volume":"2","author":"Francisco","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1039\/D0CB00199F","article-title":"Investigation of the biological functions of heparan sulfate using a chemoenzymatic synthetic approach","volume":"2","author":"Wang","year":"2021","journal-title":"RSC Chem Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2011.07.024","article-title":"Investigating the mechanism of the assembly of FGF1-binding heparan sulfate motifs","volume":"585","author":"Nguyen","year":"2011","journal-title":"FEBS Lett"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2018.04.003","article-title":"Using structurally defined oligosaccharides to understand the interactions between proteins and heparan sulfate","volume":"50","author":"Xu","year":"2018","journal-title":"Curr Opin In Struct Biol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2018.04.003","article-title":"Biology of the heparanase-heparan sulfate axis and its role in disease pathogenesis","volume":"47","author":"Vlodavsky","year":"2021","journal-title":"Semin Thromb Hemost"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.7b01399","article-title":"Heparan sulfate microarray reveals that heparan sulfate-protein binding exhibit different ligand requirements","volume":"139","author":"Zong","year":"2017","journal-title":"J Am Chem Soc"},{"key":"B66","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.matbio.2023.06.008","article-title":"Fibrolamellar carcinomas\u2013growth arrested by paracrine signals complexed with synthesized heparan sulfate oligosaccharides","volume":"121","author":"Zhang","year":"2023","journal-title":"Matrix Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2024.08.010","article-title":"Hormonally and chemically defined expansion conditions for organoids of biliary tree Stem Cells","volume":"41","author":"Zhang","year":"2024","journal-title":"Bioact Mater"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1039\/C4NP00076E","article-title":"Chemoenzymatic synthesis of heparan sulfate and heparin. Review","volume":"31","author":"Liu","year":"2014","journal-title":"Nat Prod Rep"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2014.04.024","article-title":"Hs3st3-modified heparan sulfate controls KIT+ progenitor expansion by regulating 3-O-sulfotransferases","volume":"29","author":"Patel","year":"2014","journal-title":"Dev Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1459942\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:10:13Z","timestamp":1731046213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1459942\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":69,"alternative-id":["10.3389\/fimmu.2024.1459942"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1459942","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"article-number":"1459942"}}